FLT3 and acute myeloid leukemia: Less than 60% of patients with FLT3-ITD+ AML who are over 60 years old reach complete remission and often relapse within a year with an overall relapse rate of 77%.6 For this reason, therapy efforts have focused on the development of improved FLT3-specific inhibitors, resulting in the approval of gilteritinib for use in a clinical setting.